香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 1 (1) 臨時股東會已於2025年12月30日（星期二）假座中國廣東省廣州市荔灣區沙面北街45號本公 司會議室舉行。 (2) 臨時股東會由董事會召集及由本公司董事長李小軍先生主持。本公司在任董事10人，出席 9人，其中執行董事程洪進先生因公務未能出席本次會議；董事會秘書黃雪貞女士出席了 會議。本公司高級管理人員，連同見證律師及負責點票的監票人均列席了臨時股東會。會 議的召開符合《中華人民共和國公司法》及本公司的公司章程（「公司章程」）的有關規定。 (3) 於2025年12月23日（「股權登記日」）（即釐定股東出席臨時股東會並於會上投票之權利之日 期），(i)本公司共發行1,625,790,949股股份，其中包括1,405,890,949股A股（佔已發行股份 總數約86.47%）及219,900,000股H股（佔已發行股份總數約13.53%）；(ii)公司未持有任何庫 存股。 （於中華人民共和國註冊成立 ...

证券代码：600332 证券简称：白云山 公告编号：2025-097 广州白云山医药集团股份有限公司 2025年第三次临时股东会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 | 1、出席会议的股东和代理人人数 | 647 | | --- | --- | | 其中：A 股股东人数 | 646 | | 境外上市外资股股东人数（H 股） | 1 | | 2、出席会议的股东所持有表决权的股份总数（股） | 873,410,148 | | 其中：A 股股东持有股份总数 | 838,588,017 | | 境外上市外资股股东持有股份总数（H 股） | 34,822,131 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 53.722168 | (一) 股东会召开的时间：2025 年 12 月 30 日 (二) 股东会召开的地点：广东省广州市荔湾区沙面北街 45 号本公司会议室 (三) 出席会议的普通股股东和恢 ...

二〇二五年十二月 北京市中伦（广州）律师事务所 关于广州白云山医药集团股份有限公司 2025 年第三次临时股东会的 法律意见书 北京市中伦（广州）律师事务所 关于广州白云山医药集团股份有限公司 2025 年第三次临时股东会的 法律意见书 致：广州白云山医药集团股份有限公司 北京市中伦（广州）律师事务所（以下简称"本所"）接受广州白云山医药 集团股份有限公司（以下简称"公司"）委托，指派刘子丰律师和曾道扬律师（以 下简称"本所律师"）对公司 2025 年第三次临时股东会（以下简称"本次股东会"） 的合法性进行见证并出具法律意见。 本所及本所律师依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《律师事务所从事证券法律业务管理办法》和《律师事务所证券法律业务执业规 则（试行）》等规定及本法律意见书出具日以前已经发生或者存在的事实，严格 履行了法定职责，遵循了勤勉尽责和诚实信用原则，进行了充分的核查验证，保 证本法律意见所认定的事实真实、准确、完整，所发表的结论性意见合法、准确， 不存在虚假记载、误导性陈述或者重大遗漏，并承担相应法律责任。 本法律意见书根据《中华人民共和国公司法》（以下简称"《公司法》"） ...

Core Viewpoint - The company, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited, has received approval from the National Medical Products Administration for a supplemental application regarding the drug Cefuroxime Sodium for injection, which is a second-generation cephalosporin antibiotic with broad-spectrum efficacy against both Gram-negative and Gram-positive bacteria [1] Group 1 - The approved drug, Cefuroxime Sodium, is clinically used for treating respiratory infections, urinary tract infections, and surgical infections [1] - Cefuroxime Sodium is noted for its low renal toxicity and stability against β-lactamase, making it advantageous in clinical applications [1]

Core Viewpoint - The announcement details the establishment of two funds by the subsidiary of Baiyunshan (00874), specifically the Guangyao Guangkai Fund and the Guangyao Liwan Fund, with the first fund's partnership agreement already in effect while the second is pending signature [1] Group 1 - Baiyunshan's subsidiary, Guangyao Phase II Fund, has entered into a partnership agreement for the establishment of the Guangyao Guangkai Fund with Guangyao Capital and Guangkai Fund [1] - The partnership agreement for the Guangyao Guangkai Fund became effective on December 29, 2025, with no changes to its main terms [1] - As of the date of the announcement, the partnership agreement for the Guangyao Liwan Fund has not yet been formally signed, and the company will issue a further announcement upon its signing in accordance with Hong Kong listing rules [1]

Core Viewpoint - The announcement from Baiyunshan (00874) details the establishment of the Guangyao Guangkai Fund and the Guangyao Liwan Fund through its subsidiary, Guangyao Phase II Fund, in partnership with Guangyao Capital and Guangkai Fund [1] Group 1 - The partnership agreement for the Guangyao Guangkai Fund was signed on December 29, 2025, and became effective on the same day, with no changes to the main terms of the agreement [1] - As of the date of the announcement, the partnership agreement for the Guangyao Liwan Fund has not yet been formally signed [1] - The company will issue a further announcement in accordance with Hong Kong listing rules after the signing of the partnership agreement for the Guangyao Liwan Fund [1]

Core Viewpoint - The company Baiyunshan Pharmaceutical Group has received approval from the National Medical Products Administration for its injectable Cefuroxime Sodium, enhancing its market competitiveness [1] Group 1: Product Approval - Baiyunshan Pharmaceutical's subsidiary received a notification of approval for a supplementary application for injectable Cefuroxime Sodium [1] - The product was officially launched in China in May 2006 and submitted for consistency evaluation in April 2025 [1] Group 2: Product Characteristics - Cefuroxime Sodium is a second-generation cephalosporin effective against a wide range of Gram-negative and Gram-positive bacteria, with advantages such as a broad antibacterial spectrum, lower renal toxicity, and stability against β-lactamase [1] - It is widely used in clinical settings for treating respiratory infections, urinary tract infections, and surgical infections [1] Group 3: Market Position - Injectable Cefuroxime Sodium is included in the National Essential Medicines List (2018) and is classified as a Category B drug under the National Medical Insurance (2025) [1] - The successful completion of the consistency evaluation for the generic drug is expected to enhance the product's market competitiveness [1]

Core Viewpoint - The company has received approval for its injectable Cefuroxime Sodium from the National Medical Products Administration, enhancing its market competitiveness in the pharmaceutical sector [1] Group 1: Product Approval - The Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. has received the "Drug Supplement Application Approval Notice" for its injectable Cefuroxime Sodium [1] - The injectable Cefuroxime Sodium was officially launched in China in May 2006 and submitted for consistency evaluation on April 3, 2025, with acceptance received on April 11, 2025 [1] Group 2: Product Characteristics - Cefuroxime Sodium is a second-generation cephalosporin effective against most Gram-negative and Gram-positive bacteria, known for its broad antibacterial spectrum, low renal toxicity, and stability against β-lactamase [1] - The drug is widely used in clinical settings for treating respiratory infections, urinary tract infections, and surgical infections [1] Group 3: Market Position - Injectable Cefuroxime Sodium is included in the National Essential Medicines List (2018) and classified as a Category B drug under the National Medical Insurance (2025) [1] - The successful completion of the generic drug consistency evaluation is expected to enhance the market competitiveness of the product [1]

| 投资标的名称 | 广州广药广开创业投资基金合伙企业（有限 合伙） | | | --- | --- | --- | | 投资金额（万元） | 9,750 | | | 投资进展阶段 | 完成 交易要素变更 进展 | 终止 | | 特别风险提示 | 广州广药广开创业投资基金合伙企业（有限 | | | | 合伙）尚需履行工商注册登记、中国证券投 | | | | 资基金业协会登记备案等手续，实施过程尚 | | | | 存在不确定性。 | | 一、基本情况概述 2025 年 12 月 22 日，广州白云山医药集团股份有限公司（"本公司"）召 开第九届董事会第三十二次会议，审议通过了《关于广州广药二期基金股权投资 合伙企业（有限合伙）认购广州广药广开创业投资基金合伙企业（有限合伙）有 限合伙份额暨关联交易的议案》，同意本公司附属企业广州广药二期基金股权投 资合伙企业（有限合伙）（"广药二期基金"）与广州广药资本私募基金管理有 限公司（"广药资本"）、广州开发区投资基金管理有限公司（"广开基金"） 证券代码：600332 证券简称：白云山 公告编号：2025-096 广州白云山医药集团股份有限公司 关于附属企业参 ...

证券代码：600332 证券简称：白云山 公告编号：2025-095 广州白云山医药集团股份有限公司 关于分公司获得药品补充申请批件的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，广州白云山医药集团股份有限公司（以下简称"本公司"） 分公司广州白云山医药集团股份有限公司白云山制药总厂（以下简称 "白云山制药总厂"） 收到国家药品监督管理局签发的《药品补充 申请批准通知书》。现将有关情况公告如下： 一、药品的基本情况 （一）注射用头孢呋辛钠（规格 0.25g、1.25g、1.75g、2.0g） 药品通用名称：注射用头孢呋辛钠 触药品的包装材料和容器。 审批结论：根据《中华人民共和国药品管理法》《国务院关于改 革药品医疗器械审评审批制度的意见》（国发〔2015〕44 号）、《关 于仿制药质量和疗效一致性评价工作有关事项的公告》（2017 年第 100 号）和《国家药监局关于开展化学药品注射剂仿制药质量和疗效 一致性评价工作的公告》（2020 年第 62 号）的规定，经审查，本品 通过仿制药质量和疗效一致性评价。同时同 ...